Sanofi has turned to dealmaking several times since to further build out its rare disease business. Over the past year alone, the French pharmaceutical giant nabbed rights to an experimental drug ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio ... Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys.

Sanofi currently has a Zacks Rank #2 (Buy). Some other top-ranked drug/biotech companies are Eli ... You can see the complete list of today’s Zacks #1 Rank stocks here. Estimates for Lilly ...

“There is a huge demand for these drugs at the right price.” France’s Economy Minister Antoine Armand wants guarantees from Sanofi that production of its popular Doliprane painkiller will ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...